XTANDI (enzalutamide) Patient Assistance Program
Don’t let the high cost of brand specialty prostate cancer therapy disrupt your treatment. We help eligible patients access Xtandi (enzalutamide) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Xtandi (enzalutamide) is FDA-approved for castration-resistant prostate cancer (both non-metastatic and metastatic) and for metastatic castration-sensitive prostate cancer. It is also approved for non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis. It is an oral androgen receptor inhibitor.
- Without assistance, Xtandi costs commonly run approximately $14,000–$16,500 per 30-day supply.
- Through AffordMyPrescriptions, qualifying patients can access Xtandi for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no generic Xtandi in the U.S. as of 2026. Other androgen-receptor-pathway inhibitors for prostate cancer include abiraterone (Zytiga, with multiple generics at lower cost), apalutamide (Erleada), and darolutamide (Nubeqa). Each has somewhat different indications and side-effect profiles.
What Is Xtandi Prescription Assistance Program?
The Xtandi Prescription Assistance Program is a manufacturer-sponsored initiative that provides Xtandi at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for advanced prostate cancer patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, oncology coordination, prior-authorization documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and re-certification.
Pharmacy Price Comparison
- Without assistance, Xtandi costs roughly $14,000–$16,500/month. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$16,000 | Save ~$15,930/mo |
| CVS Pharmacy | ~$16,500 | Save ~$16,430/mo |
| Walmart | ~$14,500 | Save ~$14,430/mo |
| Costco | ~$14,200 | Save ~$14,130/mo |
Specialty Pharmacy | ~$15,000 | Save ~$14,930/mo |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Xtandi Prescription Program?
The Patient Assistance Program is free to apply for and provides Xtandi at no medication cost if approved. Our $69.95/month service covers full advocacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Xtandi:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $14,000–$16,500 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Xtandi assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Xtandi Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Xtandi :
Xtandi (enzalutamide) is a once-daily oral second-generation androgen receptor inhibitor used to treat advanced prostate cancer. It blocks androgen receptor signaling at multiple points — preventing androgen binding, blocking nuclear translocation, and inhibiting DNA binding — providing more complete androgen pathway blockade than first-generation antiandrogens.
How Xtandi Works:
Enzalutamide is a second-generation androgen receptor (AR) inhibitor designed to treat prostate cancer, which relies heavily on androgen signaling for growth. It works by binding to the AR with high affinity, blocking androgen binding, preventing the receptor’s nuclear translocation, and inhibiting its interaction with DNA. This comprehensive pathway blockade successfully delays disease progression, reduces symptoms, and improves overall survival. It remains clinically effective even in advanced, castration-resistant stages of the disease where tumors have learned to grow despite low testosterone levels.
Form and use:
Sold under the brand name Xtandi, this medication is administered orally as a 160 mg dose taken once daily, which consists of four 40 mg capsules or tablets. It can be taken either with or without food according to patient preference. Patients are generally required to maintain concurrent androgen deprivation therapy, such as an LHRH agonist/antagonist or surgical castration, throughout the treatment. Additionally, adjustments or avoidance may be necessary if the patient is taking strong CYP3A4 inducers.
Generic availability:
As of 2026, there is no generic version of Xtandi available in the United States. Other alternative androgen-receptor-pathway inhibitors include apalutamide, darolutamide (which may feature less CNS penetration), and abiraterone acetate. Abiraterone acetate works upstream by blocking CYP17 androgen synthesis and currently has multiple generic options available at a substantially lower cost. Because of this, generic abiraterone stands out as often being the most cost-effective AR-pathway therapy available to patients.
Warnings:
Xtandi carries notable warnings for seizures, meaning it should be avoided in patients with a history of seizures or predisposing risk factors. It is also associated with risks of posterior reversible encephalopathy syndrome (PRES), hypersensitivity reactions, ischemic heart disease, and an increased risk of falls and fractures. The drug causes embryo-fetal toxicity, requiring male patients to use condoms during treatment and for three months afterward. Furthermore, it presents significant drug interactions; strong CYP3A4 inducers lower its efficacy, while enzalutamide itself acts as a moderate CYP3A4 inducer that can reduce the effectiveness of many co-administered medications.
FAQ (Frequently Asked Questions)
How Much Does Xtandi Cost Without Insurance?
Xtandi costs approximately $14,000–$16,500 per 30-day supply. Through AffordMyPrescriptions, qualifying patients receive Xtandi at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
How Is Xtandi Different From Zytiga?
Both target androgen signaling in prostate cancer. Xtandi (enzalutamide) directly blocks the androgen receptor — taken once daily without food restriction or steroid coadministration. Zytiga (abiraterone) blocks androgen SYNTHESIS by inhibiting CYP17 — must be taken on an empty stomach AND requires concurrent prednisone (5–10 mg/day) to prevent mineralocorticoid effects. With generic abiraterone now available at substantially lower cost, abiraterone is often the more affordable option, though enzalutamide doesn’t require steroid co-administration.
Should I Try Generic Abiraterone First?
This is a clinical decision between you and your oncologist. Both Xtandi and generic abiraterone are effective in similar prostate cancer settings. Generic abiraterone is dramatically cheaper. Some patients tolerate one better than the other — and the choice often comes down to insurance coverage, steroid tolerance (Zytiga requires prednisone), seizure risk (Xtandi has seizure warning), and dosing/food preferences. Many oncologists try abiraterone first when cost is a major factor.
Will I Still Need Hormone Injections?
Yes, in most cases. Xtandi is typically used concurrently with androgen deprivation therapy (LHRH agonists like Lupron, LHRH antagonists like Firmagon or Orgovyx) — not as a replacement. The combined approach provides more complete androgen pathway blockade than either alone. The exception is patients who have undergone surgical castration (bilateral orchiectomy).
Are There Drug Interactions I Should Know About?
Yes. Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, phenobarbital, St. John’s wort) substantially reduce enzalutamide levels and should be avoided. Enzalutamide itself induces CYP3A4 and CYP2C9 — reducing levels of many co-administered drugs including warfarin (reduces effect), some statins, some antiepileptics, opioids, and others. Tell every prescriber and pharmacist about Xtandi.
Can I Get Xtandi Through The PAP If I Have Medicare?
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
What If My Application Is Denied?
If denied, we explore alternatives — switching to generic abiraterone (substantially cheaper) with prednisone, Erleada or Nubeqa with their own PAPs, the manufacturer’s copay program for commercially insured patients, or independent foundations such as the Prostate Cancer Foundation, ZERO Prostate Cancer, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Xtandi, our team may be able to help you access assistance programs designed to make brand specialty prostate cancer therapy affordable. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.